A Multicenter, Open-Label, Safety Study of Meloxicam SoluMatrix Capsules in Subjects With Osteoarthritis of the Knee or Hip

Trial Profile

A Multicenter, Open-Label, Safety Study of Meloxicam SoluMatrix Capsules in Subjects With Osteoarthritis of the Knee or Hip

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Meloxicam (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Iroko Pharmaceuticals
  • Most Recent Events

    • 30 Mar 2016 New analyses of data from this trial will be presented at the 2016 Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, according to an Iroko media release.
    • 23 Oct 2015 According to an Iroko Pharmaceuticals media release, the NDA application to the US FDA include data from this trial.
    • 12 Mar 2015 The US FDA accepted for review the NDA for SoluMatrix meloxicam, which was based on data from this trial and a phase III efficacy study, according to an Iroko Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top